About Genesis Therapeutics
Genesis Therapeutics is a company based in San Francisco (United States) founded in 2019 by Ben Sklaroff, James Schaeffer, and Evan Feinberg. Genesis Therapeutics has raised $304.02 million across 5 funding rounds from investors including Fidelity Investments, BlackRock and T. Rowe Price. Genesis Therapeutics operates in a competitive market with competitors including Relay Therapeutics, Atomwise, Unnatural Products, neoX Biotech and Celeris Therapeutics, among others.
- Headquarter San Francisco, United States
- Founders Ben Sklaroff, James Schaeffer, Evan Feinberg
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genesis Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$304.02 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Fidelity Investments
& 15 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Genesis Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Genesis Therapeutics
Genesis Therapeutics has successfully raised a total of $304.02M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genesis Therapeutics
Genesis Therapeutics has secured backing from 16 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, BlackRock and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital arm of Nvidia
|
Locked | Locked | Locked | |
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on AI-driven companies
|
Locked | Locked | Locked |
Investor details for Genesis Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genesis Therapeutics
Investment portfolio details for Genesis Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genesis Therapeutics
Detailed financials for Genesis Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genesis Therapeutics Comparisons
Peer comparison for Genesis Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genesis Therapeutics
Genesis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Relay Therapeutics, Atomwise, Unnatural Products, neoX Biotech and Celeris Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery platform is developed to study protein motion.
|
|
| Locked | Locked | Locked |
AI-driven platform for structure-based drug discovery is provided.
|
|
| Locked | Locked | Locked |
Peptides are engineered via computational biology for undruggable targets.
|
|
| Locked | Locked | Locked |
Protein-protein interactions are researched and characterized to aid drug discovery.
|
|
| Locked | Locked | Locked |
An AI-driven degrader platform for drug discovery is developed.
|
Detailed competitors of Genesis Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genesis Therapeutics
Complete news archive for Genesis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genesis Therapeutics
Genesis Therapeutics was founded in 2019.
Genesis Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Evan Feinberg is the current CEO of Genesis Therapeutics. They have also founded this company.
Genesis Therapeutics is a funded company, having raised a total of $304.02M across 5 funding rounds to date.
Genesis Therapeutics was founded in 2019 in San Francisco, United States, within the biotechnology sector. A computational platform is utilized for small molecule drug discovery, incorporating artificial intelligence. Neural networks and biophysical simulations are integrated with a scalable computing infrastructure to support drug design and development. Operations center on enhancing efficiency in pharmaceutical innovation through these methods.
Genesis Therapeutics's top competitors include Atomwise, Unnatural Products and Relay Therapeutics.
Genesis Therapeutics has 16 investors. Key investors include Fidelity Investments, BlackRock, T. Rowe Price, NVentures, and Andreessen Horowitz.